NCT03109080View on ClinicalTrials.gov

Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 24, 2017

Primary Completion Date

February 17, 2020

Study Completion Date

November 29, 2021

Conditions
Breast Neoplasms, Triple-NegativeBreast Neoplasm Malignant FemaleRadiotherapy Side Effect
Interventions
DRUG

Olaparib

five levels of dose, per os administration, twice daily each day

RADIATION

Radiation therapy

3D conformal radiotherapy or intensity-modulated radiotherapy (IMRT), Simultaneous Integrated Boost (SIB), postoperative radiotherapy

Trial Locations (1)

75005

Institut Curie, Paris

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Institut Curie

OTHER